Live Stock Coverage: Is Cyclacel Pharmaceuticals Inc a Sell? The Stock Reaches All-Time Low Today

Live Stock Coverage: Is Cyclacel Pharmaceuticals Inc a Sell? The Stock Reaches All Time Low Today

The stock of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) reached all time low today, Nov, 4 and still has $3.03 target or 11.00% below today’s $3.40 share price. This indicates more downside for the $12.26 million company. This technical setup was reported by Barchart.com. If the $3.03 PT is reached, the company will be worth $1.35 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 10,978 shares traded hands. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has declined 30.00% since April 4, 2016 and is downtrending. It has underperformed by 31.09% the S&P500.

Analysts await Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to report earnings on November, 10. They expect $-0.94 EPS, up 2.08% or $0.02 from last year’s $-0.96 per share. After $-1.01 actual EPS reported by Cyclacel Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -6.93% EPS growth.

According to Zacks Investment Research, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.”

Insitutional Activity: The institutional sentiment decreased to 0.09 in 2016 Q2. Its down 3.58, from 3.67 in 2016Q1. The ratio is negative, as 23 funds sold all Cyclacel Pharmaceuticals Inc shares owned while 0 reduced positions. 2 funds bought stakes while 0 increased positions. They now own 13,631 shares or 99.80% less from 6.70 million shares in 2016Q1.
Baker Bros Limited Partnership has 0% invested in the company for 13,253 shares. The New York-based Tower Cap Limited (Trc) has invested 0% in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC).

More important recent Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on September 11, 2009, also Investorplace.com published article titled: “Cyclacel Pharmaceuticals Inc (CYCC): Don’t Believe the Hype”, Seekingalpha.com published: “Cyclacel Pharmaceuticals, Inc.’s (CYCC) CEO Spiro Rombotis on Q2 2016 Results …” on August 10, 2016. More interesting news about Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) was released by: Quotes.Wsj.com and their article: “News Cyclacel Pharmaceuticals Inc.CYCC” with publication date: February 11, 2011.

CYCC Company Profile

Cyclacel Pharmaceuticals, Inc., incorporated on January 5, 1996, operates in the field of cell cycle biology. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Company’s family of anticancer drugs acts on the cell cycle.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment